Zevra Therapeutics to Participate at Upcoming Investor Conferences
Zevra Therapeutics (ZVRA), a commercial-stage rare disease therapeutics company, has announced its participation in two major investor conferences in February 2025. The company's executive leadership team will present at the Guggenheim Securities SMID Cap Biotechnology Conference on February 5 at 2:30 p.m. ET, and the Oppenheimer & Co. 35th Annual Healthcare Life Sciences Conference on February 12 at 3:20 p.m. ET.
Management will be available for one-on-one meetings with registered attendees at both conferences. Interested parties can access live webcasts of the presentations through the 'Events & Presentations' section on Zevra's Investor Relations website at investors.zevra.com.
Zevra Therapeutics (ZVRA), un'azienda che opera nel settore delle terapie per malattie rare e in fase commerciale, ha annunciato la sua partecipazione a due importanti conferenze per investitori nel febbraio 2025. Il team dirigenziale dell'azienda presenterà alla Guggenheim Securities SMID Cap Biotechnology Conference il 5 febbraio alle 14:30 ET e alla Oppenheimer & Co. 35th Annual Healthcare Life Sciences Conference il 12 febbraio alle 15:20 ET.
La direzione sarà a disposizione per incontri individuali con i partecipanti registrati in entrambe le conferenze. Le parti interessate possono accedere alle trasmissioni in diretta delle presentazioni attraverso la sezione 'Eventi e Presentazioni' sul sito web delle Relazioni con gli Investitori di Zevra su investors.zevra.com.
Zevra Therapeutics (ZVRA), una empresa en fase comercial de terapias para enfermedades raras, ha anunciado su participación en dos importantes conferencias para inversores en febrero de 2025. El equipo ejecutivo de la empresa presentará en la Guggenheim Securities SMID Cap Biotechnology Conference el 5 de febrero a las 2:30 p.m. ET, y en la Oppenheimer & Co. 35th Annual Healthcare Life Sciences Conference el 12 de febrero a las 3:20 p.m. ET.
La dirección estará disponible para reuniones individuales con los asistentes registrados en ambas conferencias. Las partes interesadas pueden acceder a las transmisiones en vivo de las presentaciones a través de la sección 'Eventos y Presentaciones' en el sitio web de Relaciones con Inversores de Zevra en investors.zevra.com.
제브라 치료제(ZVRA), 상업 단계의 희귀 질환 치료제 회사가 2025년 2월 두 개의 주요 투자자 컨퍼런스에 참여한다고 발표했습니다. 회사의 경영진은 2월 5일 오후 2시 30분(동부시간) 구겐하임 증권 SMID 캡 생명공학 컨퍼런스와 2월 12일 오후 3시 20분(동부시간) 오펜하이머 & 회사 제35회 연례 건강 과학 컨퍼런스에서 발표합니다.
경영진은 두 컨퍼런스에서 등록된 참석자와의 일대일 회의에 참석할 수 있습니다. 관심 있는 당사자는 Zevra의 투자자 관계 웹사이트인 investors.zevra.com의 '이벤트 및 발표' 섹션을 통해 발표의 실시간 웹캐스트에 접근할 수 있습니다.
Zevra Therapeutics (ZVRA), une entreprise spécialisée dans les thérapies pour les maladies rares et en phase commerciale, a annoncé sa participation à deux grandes conférences pour investisseurs en février 2025. L'équipe de direction de l'entreprise présentera à la Guggenheim Securities SMID Cap Biotechnology Conference le 5 février à 14h30 ET, et à la Oppenheimer & Co. 35th Annual Healthcare Life Sciences Conference le 12 février à 15h20 ET.
La direction sera disponible pour des réunions individuelles avec les participants enregistrés lors des deux conférences. Les personnes intéressées peuvent accéder aux diffusions en direct des présentations via la section 'Événements & Présentations' sur le site de Relations Investisseurs de Zevra à investors.zevra.com.
Zevra Therapeutics (ZVRA), ein Unternehmen für therapeutische Anwendungen bei seltenen Erkrankungen in der Kommerzialisierungsphase, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im Februar 2025 bekannt gegeben. Das Führungsteam des Unternehmens wird am 5. Februar um 14:30 Uhr ET auf der Guggenheim Securities SMID Cap Biotechnology Conference und am 12. Februar um 15:20 Uhr ET auf der Oppenheimer & Co. 35th Annual Healthcare Life Sciences Conference präsentieren.
Das Management steht registrierten Teilnehmern auf beiden Konferenzen für Einzelgespräche zur Verfügung. Interessierte können die Live-Webcasts der Präsentationen über den Bereich 'Veranstaltungen & Präsentationen' auf der Investor-Relations-Website von Zevra unter investors.zevra.com abrufen.
- None.
- None.
CELEBRATION, Fla., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage rare disease therapeutics company, today announced that members of Zevra’s executive leadership team will participate in the following February events.
- Guggenheim Securities SMID Cap Biotechnology Conference on Wednesday, Feb. 5, 2025, at 2:30 p.m. ET.
- Oppenheimer & Co. 35th Annual Healthcare Life Sciences Conference on Wednesday, Feb. 12, 2025, at 3:20 p.m. ET.
Additionally, management will be available for one-on-one meetings with registered attendees at each conference. The live webcasts will be accessible via “Events & Presentations” on the Investor Relations section of Zevra’s website at investors.zevra.com.
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community.
For more information, please visit www.zevra.com or follow us on X (formerly Twitter) and LinkedIn.
Caution Concerning Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding upcoming events or Zevra’s participation at such events. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra’s Annual Report on Form 10-K for the year ended Dec. 31, 2023, Zevra’s Quarterly Report for the quarter ended Sept. 30, 2024, and Zevra’s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.
Zevra Contact
Nichol Ochsner
+1 (732) 754-2545
nochsner@zevra.com
This press release was published by a CLEAR® Verified individual.
FAQ
When is Zevra Therapeutics (ZVRA) presenting at the Guggenheim Securities Conference in February 2025?
What time is ZVRA's presentation at the Oppenheimer Healthcare Conference in February 2025?
How can investors access Zevra Therapeutics' (ZVRA) February 2025 conference presentations?
Will ZVRA management be available for one-on-one meetings at the February 2025 conferences?
